8th Apr 2005 14:00
Skyepharma PLC08 April 2005 For Immediate Release 8 April 2005 SkyePharma to Announce 2004 Full Year Results on 28 April and to Host Analyst Presentation and Conference Call LONDON & NEW YORK, 8 April 2004 -- SkyePharma PLC (LSE: SKP; Nasdaq: SKYE)announces today that the Company will announce the financial results for theyear ended 31 December 2004 to the London Stock Exchange at 07:00 a.m. (BST) onThursday 28 April 2005. Later that day the Company will host an analystpresentation, which will be webcast live, and a US conference call to reviewthese results. Michael Ashton, SkyePharma's Chief Executive Officer, will host the analystpresentation and the conference call. Investors and other interested parties mayview the live webcast at 10:00 a.m. (BST) on the Company's website atwww.skyepharma.com under the Investor Relations tab. US Investors and other interested parties may access the conference call at 10:00 a.m. EDT (15:00 BST) by dialling (888)-428-4469 for US participants and+1-651-291-5254 for international participants. The slides of the presentationwill be available on the Company's website at www.skyepharma.com under theInvestor Relations tab. For those unable to listen to the live broadcast, a replay will be availableshortly after the conference call by dialling (800)-475-6701 for US participantsand +1-320-365-3844 for international participants and entering Access Code778172. For further information please contact: SkyePharma PLC +44 207 491 1777Michael Ashton, Chief Executive OfficerPeter Laing, Director of Corporate Communications +44 207 491 5124Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000Tim Anderson / Mark Court About SkyePharma PLC SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now ten approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. Except for the historical information herein, the matters discussed in this newsrelease include forward-looking statements that may involve a number of risksand uncertainties. Actual results may vary significantly based upon a number offactors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. These include without limitation risks in obtaining andmaintaining regulatory approval for existing, new or expanded indications forits products, other regulatory risks, risks relating to SkyePharma's ability tomanufacture pharmaceutical products on a large scale, risks that customerinventory will be greater than previously thought, risks concerning SkyePharma'sability to manage growth, SkyePharma's marketing partners' ability to market apharmaceutical product on a large scale and manage their sales and marketingorganisation and maintain or expand sales and market share for its products,risks relating to the ability to ensure regulatory compliance, risks related tothe research, development and regulatory approval of new pharmaceuticalproducts, risks related to research and development costs and capabilities,market acceptance of and continuing demand for SkyePharma's products and theimpact of increased competition, risks associated with anticipated top andbottom line growth and the possibility that upside potential will not beachieved, competitive products and pricing, and risks associated with theownership and use of intellectual property rights. SkyePharma undertakes noobligation to revise or update any such forward-looking statement to reflectevents or circumstances after the date of this release. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L